ONO-4578
- Generic Name
- ONO-4578
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 144
- Registration Number
- NCT06948448
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
- Conditions
- Metastatic Breast CancerHormone Receptor-positive Breast CancerHER2-negative Breast CancerRecurrent Breast Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06570031
- Locations
- 🇯🇵
Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06547385
- Locations
- 🇯🇵
Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan
🇯🇵Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi, Osaka, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT06542731
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇯🇵The Cancer Institute Hospital of JFCR, Koto-ku, Japan
🇯🇵Teikyo University Hospital, Itabashi-ku, Japan
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06538207
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 210
- Registration Number
- NCT06256328
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT03661632
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 183
- Registration Number
- NCT03155061
- Locations
- 🇯🇵
Aichi Clinical Site 1, Nagoya, Aichi, Japan
🇯🇵Osaka Clinical Site 4, Takatsuki, Osaka, Japan
🇯🇵Aichi Clinical Site 2, Toyoake, Aichi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.